Archaeosomes with encapsulated antigens for oral vaccine delivery

Vaccine

Volumn 29, Issue 32, 2011, Pages 5260-5266

  Li, Zhengrong ^a   Zhang, Lihui ^b   Sun, Wenqiang ^b   Ding, Qian ^b   Hou, Yongtai ^b   Xu, Yuhong ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Archaeosomes; Liposomes; Oral delivery; Vaccine

Indexed keywords

ANTIGEN; ARCHAEOSOME; CD8 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LIPOSOME; OVALBUMIN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INTESTINE FLUID; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SIMULATION; STOMACH JUICE; SULFOLOBUS ACIDOCALDARIUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL TRACT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPIDS; LIPOSOMES; MICE; MICE, INBRED BALB C; OVALBUMIN; SULFOLOBUS ACIDOCALDARIUS; VACCINES;

EID: 79960336687     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.015     Document Type: Article

References (47)

1. Holmgren J., Czerkinsky C., Eriksson K., Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003, 21(Suppl. 2):S89-95.
2. Yuki Y., Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol 2003, 13(5):293-310.
3. Allemann E., Leroux J., Gurny R. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev 1998, 34(2-3):171-189.
4. Jung T., Kamm W., Breitenbach A., Kaiserling E., Xiao J.X., Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?. Eur J Pharm Biopharm 2000, 50(1):147-160.
5. des Rieux A., Fievez V., Garinot M., Schneider Y.J., Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006, 116(1):1-27.
6. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001, 51(1-3):81-96.
7. Regnstrom K., Ragnarsson E.G., Koping-Hoggard M., Torstensson E., Nyblom H., Artursson P. PEI-a potent, but not harmless, mucosal immuno-stimulator of mixed T-helper cell response and FasL-mediated cell death in mice. Gene Ther 2003, 10(18):1575-1583.
8. O'Hagan D.T. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev 1998, 34(2-3):305-320.
9. Minato S., Iwanaga K., Kakemi M., Yamashita S., Oku N. Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity. J Control Release 2003, 89(2):189-197.
10. Soares A.F., Carvalho Rde A., Veiga F. Oral administration of peptides and proteins: nanoparticles and cyclodextrins as biocompatible delivery systems. Nanomed 2007, 2(2):183-202.
11. Rogers J.A., Anderson K.E. The potential of liposomes in oral drug delivery. Crit Rev Ther Drug Carrier Syst 1998, 15(5):421-480.
12. Lasic D.D. Novel applications of liposomes. Trends Biotechnol 1998, 16(7):307-321.
13. Patel G.B., Agnew B.J., Deschatelets L., Fleming L.P., Sprott G.D. In vitro assessment of archaeosome stability for developing oral delivery systems. Int J Pharm 2000, 194(1):39-49.
14. Sprott G.D., Dicaire L.P., Fleming L.P., Patel G.B. Stability of liposomes prepared from archaeobacterial lipids and phosphatidylcholine mixtures. Cells Mater 1996, 6:143-155.
15. Choquet C.G., Patel G.B., Sprott G.D., Beveridge T.J. Stability of pressure-extruded liposomes made from archaeobacterial ether lipids. Appl Microbiol Biotechnol 1994, 42(2):375-384.
16. Patel G.B., Chen W. Archaeosome immunostimulatory vaccine delivery system. Curr Drug Deliv 2005, 2(4):407-421.
17. Krishnan L., Dicaire C.J., Patel G.B., Sprott G.D. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect Immun 2000, 68(1):54-63.
18. Krishnan L., Sad S., Patel G.B., Sprott G.D. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help. J Immunol 2000, 165(9):5177-5185.
19. Omri A., Agnew B.J., Patel G.B. Short-term repeated-dose toxicity profile of archaeosomes administered to mice via intravenous and oral routes. Int J Toxicol 2003, 22(1):9-23.
20. Patel G.B., Omri A., Deschatelets L., Sprott G.D. Safety of archaeosome adjuvants evaluated in a mouse model. J Liposome Res 2002, 12(4):353-372.
21. Jacquemet A., Barbeau J., Lemiegre L., Benvegnu T. Archaeal tetraether bipolar lipids: structure, function and applications. Biochimie 2009, 91:711-717.
22. Elferink M.G., de Wit J.G., Demel R., Driessen A.J., Konings W.N. Functional reconstitution of membrane proteins in monolayer liposomes from bipolar lipids of Sulfolobus acidocaldarius. J Biol Chem 1992, 267(2):1375-1381.
23. Brown D.A., Venegas B., Cooke P.H., English V., Chong P.L. Bipolar tetraether archaeosomes exhibit unusual stability against autoclaving as studied by dynamic light scattering and electron microscopy. Chem Phys Lipids 2009, 159(2):95-103.
24. Patel G.B., Ponce A., Zhou H., Chen W. Structural characterization of archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) formulations prepared by different protocols and their efficacy upon intranasal immunization of mice. J Liposome Res 2008, 18(2):127-143.
25. Lo S.L., Chang E.L. Purification and characterization of a liposomal-forming tetraether lipid fraction. Biochem Biophys Res Commun 1990, 167(1):238-243.
26. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37(8):911-917.
27. Li Z.R., Zhang L.H., Xu Y.H. The preparation and stability evaluation of archaeosomes consisted of tetraetherlipids from Sulfolobus acidocaldarius. Acta Biophys Sin 2010, 26(12):1101-1110.
28. Fan Q., Relini A., Cassinadri D., Gambacorta A., Gliozzi A. Stability against temperature and external agents of vesicles composed of archael bolaform lipids and egg PC. Biochim Biophys Acta 1995, 1240(1):83-88.
29. New RRC. Liposomes: a practical approach, p. 58-9.
30. Allen T.M., Cleland L.G. Serum-induced leakage of liposome contents. Biochim Biophys Acta 1980, 597(2):418-426.
31. Slepushkin V.A., Simoes S., Dazin P., Newman M.S., Guo L.S., Pedroso de Lima M.C., et al. Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo. J Biol Chem 1997, 272(4):2382-2388.
32. Momekova D., Rangelov S., Yanev S., Nikolova E., Konstantinov S., Romberg B., et al. Long-circulating, pH-sensitive liposomes sterically stabilized by copolymers bearing short blocks of lipid-mimetic units. Eur J Pharm Sci 2007, 32(4-5):308-317.
33. Benvegnu T., Rethore G., Brard M., Richter W., Plusquellec D. Archaeosomes based on novel synthetic tetraether-type lipids for the development of oral delivery systems. Chem Commun (Camb) 2005, 28(44):5536-5538.
34. Lee H., Park T.G. Preparation and characterization of mono-PEGylated epidermal growth factor: evaluation of in vitro biologic activity. Pharm Res 2002, 19(6):845-851.
35. Park K., Kim J.H., Nam Y.S., Lee S., Nam H.Y., Kim K., et al. Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release 2007, 122(3):305-314.
36. Song S., Liu D., Peng J., Sun Y., Li Z., Gu J.R., et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm 2008, 363(1-2):155-161.
37. Li Z.R., Chen J., Sun W.Q., Xu Y.H. Investigation of archaeosomes as carriers for oral delivery of peptides. Biochem Biophys Res Commun 2010, 394(2):412-417.
38. Sprott G.D. Structures of archaeobacterial membrane lipids. J Bioenergy Biomembr 1992, 24:555-566.
39. Glueck R. Review of intranasal influenza vaccine. Adv Drug Deliv Rev 2001, 51(1-3):203-211.
40. Mestecky J., Moldoveanu Z., Michalek S.M., Morrow C.D., Compans R.W., Schafer D.P., et al. Current options for vaccine delivery systems by mucosal routes. J Control Release 1997, 48(2-3):243-257.
41. Jones N. The nose and paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev 2001, 51(1-3):5-19.
42. Ogue S., Takahashi Y., Onishi H., Machida Y. Preparation of double liposomes and their efficiency as an oral vaccine carrier. Biol Pharm Bull 2006, 29(6):1223-1228.
43. Venkatesan N., Vyas S.P. Polysaccharide coated liposomes for oral immunization-development and characterization. Int J Pharm 2000, 203(1-2):169-177.
44. Brayden D.J., Baird A.W. Apical membrane receptors on intestinal M cells: potential targets for vaccine delivery. Adv Drug Deliv Rev 2004, 56(6):721-726.
45. Shakweh M., Ponchel G., Fattal E. Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin Drug Deliv 2004, 1(1):141-163.
46. Sprott G.D., Sad S., Fleming L.P., Dicaire C.J., Patel G.B., Krishnan L. Archaeosomes varying in lipid composition differ in receptor-mediated endocytosis and differentially adjuvant immune responses to entrapped antigen. Archaea 2003, 1(3):151-164.
47. Krishnan L., Sprott G.D. Archaeosome adjuvants: immunological capabilities and mechanism(s) of action. Vaccine 2008, 26(17):2043-2055.